Eli Lilly's combo of Zepbound and amylin-targeting eloralintide yields 23.3% weight loss in mid-stage trial, though tolerability woes loom.
As an Amazon Associate, Clay Tribune earns from qualifying purchases.
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
We carry advertising, and we like to know what gets read. Both use cookies. They are on unless you say otherwise, and you can opt out at any time from the link below.